Trial · NCT06106945
Registered outcomes29
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
21 to 29 of 29
Download this page as JSON| List | Outcome | Time frame | Description |
|---|---|---|---|
| Secondary | Phase Ib: Pharmacokinetics of AZD0305: Maximum plasma concentration of the study drug (Cmax) | From randomization/cohort assignment , at predefined intervals throughout the administration of AZD0305 (approximately 2 years) | Maximum observed plasma concentration of the study drug |
| Secondary | Phase Ib: Pharmacokinetics of AZD0305: Time to maximum plasma concentration of the study drug (tmax) | From randomization/cohort assignment , at predefined intervals throughout the administration of AZD0305 (approximately 2 years) | Time to maximum observed plasma concentration of the study drug |
| Secondary | Phase Ib: Pharmacokinetics of AZD0305: Clearance | From randomization/cohort assignment , at predefined intervals throughout the administration of AZD0305 (approximately 2 years | A pharmacokinetic measurement of the volume of plasma from which the study drug is completely removed per unit time |
| Secondary | Phase Ib: Pharmacokinetics of AZD0305: Terminal elimination half-life (t 1/2) | From randomization/cohort assignment, at predefined intervals throughout the administration of AZD0305 (approximately 2 years) | Terminal elimination half-life |
| Secondary | Phase Ib: Immunogenicity of AZD0305 | From randomization/cohort assignment, at predefined intervals throughout the administration of AZD0305 (approximately 2 years) | The number and percentage of participants who develop ADAs |
| Secondary | Phase Ib: Immunogenicity of elranatamab | From the first dose, at predefined intervals until Cycle 24 administration of elranatamab(approximately 2 years) | The number and percentage of participants who develop ADAs |
| Secondary | Phase 1b: MRD negative CR rate (Module 2 and Module 3) | From first dose of AZD0305 to progressive disease or death in the absence of disease progression (approximately 2 years) | The percentage of patients who achieve a complete response (CR) and have minimal residual disease (MRD) negativity in bone marrow. |
| Secondary | Complete Response Rate (CRR) - Mod2&3 only | From first dose of combination treatment to progressive disease or initiation of subsequent multiple myeloma therapy (approximately 2 years) | Percentage of participants achieving a confirmed CR or sCR per IMWG criteria. |
| Secondary | Pre-Dose Plasma Concentration of Elranatamab (pharmacokinetics - Module 2 only) | From the first dose of study intervention, at predefined intervals until Cycle 24 administration of elranatamab(approximately 2 years; 1 cycle = 28 days) | Pre-dose Plasma concentrations for elranatamab. |
Source ClinicalTrials.govtrials-2026-11-12-0.5.0
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/trials/v1/NCT06106945/registered?page=2